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Keliakian hoidossa käytettävää tiukkaa gluteenitonta ruokavaliota voisi monipuolistaa puhtaalla 
kauralla. Joidenkin tutkimusten mukaan kaura voi kuitenkin aiheuttaa oireita ja jopa 
ohutsuolivaurioita, mutta asiasta on vain vähän pitkäaikaistutkimusta. Vertasimme pitkäaikaisen 
gluteenittoman ruokavaliohoidon tuloksia kauraa käyttävien ja kauraa käyttämättömien 
keliaakikkojen välillä. Tutkimme myös mitkä tekijät vaikuttavat kauran käytön aloittamiseen.  
Maanlaajuiseen tutkimukseen osallistui 869 aiemmin diagnosoitua keliaakikkoa, joiden 
gluteenittoman ruokavaliohoidon mediaanikesto oli 10 vuotta. Laajan haastattelun lisäksi he 
täyttivät validoidut GSRS-, PGWB- ja SF-36-kyselylomakkeet oireiden ja elämänlaadun 
selvittämiseksi. Lisäksi heiltä määritettiin keliakiavasta-ainetasot verinäytteestä.  Sairaustiedot ja 
kontrollitähystyksen tulokset tarkastettiin potilaskertomuksista. 
Kaikkiaan 82 % käytti kauraa osana gluteenitonta ruokavaliotaan. Kauran käyttöä ennustavia 
tekijöitä olivat diagnoosi vuoden 2000 jälkeen, diagnoosin saaminen seulonnassa ja lievät kliiniset 
oireet. Kauran käyttäjät ja ei-käyttäjät eivät eronneet ruokavalion noudattamisessa (96.5% vs 
97.4%, p=0.746), nykyisten oireiden esiintyvyydessä (22.9% vs 22.5%, p=0.931), keliakiavasta-
ainepositiivisuudessa (8.8% vs 6.0%, p=0.237), suolinukkavaurion paranemisessa vuoden jälkeen 
(63.1% vs 60.0%, p=0.773), maligniteeteissä (4.8% vs 3.3%, p=0.420), 
osteoporoosissa/osteopeniassa (9.2% vs 11.0%, p=0.489) tai murtumissa (26.9% vs 27.9%, 
p=0.791). Ainoa merkitsevä ero kyselylomakkeissa oli kauran käyttäjien paremmat pisteet 
fyysisissä roolirajoituksissa (p=0.020) ja yleisterveydessä (p=0.048). 
Tulokset antavat vahvaa näyttöä, että kauran pitkäaikaiskäyttö keliakiassa on turvallista ja voi 
vaikuttaa myönteisesti terveyteen ja elämänlaatuun. 
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Abstract: 
Background & Aims: A strict gluten-free diet (GFD) can be diversified by non-contaminated oats, 
but there is a shortage of long-term studies concerning its safety. We compared long-term treatment 
outcomes and factors associated with the introduction of oats between celiac patients on a GFD 
with or without oats.  
Methods: Eight hundred sixty-nine previously diagnosed celiac patients were interviewed. The 
validated Gastrointestinal Symptom Rating Scale (GSRS), Psychological General Well-Being 
(PGWB), and Short-Form 36 Health Survey (SF-36) questionnaires were used to assess symptoms 
and quality of life, serological tests were performed, and results of histology were confirmed from 
patient records. 
Results: We found the median duration of GFD to be 10 years and 82% using oats. Factors 
predicting the consumption of oats were diagnosis after the year 2000, advice from a dietitian, 
detection by screening, and mild clinical presentation. Oat consumers and non-consumers did not 
differ in dietary adherence (96.5% vs. 97.4%, p = 0.746), the prevalence of symptoms (22.9% vs. 
22.5%, p = 0.931), positivity for endomysial antibodies (8.8% vs. 6.0%, p = 0.237), histological 
recovery after one year (63.1% vs. 60.0%, p = 0.773), malignancy (4.8% vs. 3.3%, p = 0.420), 
osteoporosis/osteopenia (9.2% vs. 11.0%, p = 0.489), or fractures (26.9% vs. 27.9%, p = 0.791). 
The oat consumers had better SF-36 physical role limitations and general health scores.  
Conclusions: Based on our results, the long-term consumption of oats in celiac disease patients is 
safe and may improve quality of life. 
 
Keywords: gluten-free diet; treatment; complications; symptoms; quality of life 
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1. Introduction 
By reason of increasing recognition of the diverse clinical presentation of celiac disease, combined 
with new serological tools for its detection, the condition has emerged as one of the most common 
nutrition-related diseases [1, 2]. The true incidence of the disease seems also to be rising, further 
emphasizing the considerable public health and economic significance of its optimal management 
[3, 4]. In theory, treatment is simple, as the essential environmental trigger, gluten, is known and 
can be eliminated by a gluten-free diet (GFD). Notwithstanding its undisputable beneficial effects, a 
life-long GFD has its disadvantages. It is challenging to maintain and may lead to a restricted and 
nutritionally suboptimal diet. Further, many GFD products have low fiber and high fat and sugar 
content, predisposing patients for example to constipation, obesity, and cardiovascular diseases [5, 
6].  
The mainstay of the GFD is the exclusion of dietary wheat, barley, and rye, while the consumption 
of oats remains controversial. Oats have different storage protein composition than the three other 
cereals, and the short-term safety of oats in celiac disease patients was proposed as far back as the 
1990s [7] and further supported by subsequent clinical trials [8–10]. In some studies, however, oats 
were found to cause symptoms or even occasional small-intestinal damage [11, 12] or to trigger 
immunological responses in experimental models [13, 14]. The possibility of using oats would have 
a major health impact, as it is nutritious and a good source of fiber, which may reduce constipation 
and the risk of type 2 diabetes [8]. Oats may also lower harmful cholesterol levels, enhance immune 
defense, and protect against heart disease and cancer [15–17]. Finally, oats could diversify the GFD 
and reduce individual fat and sugar intake. The main limitation in the current evidence of the 
consumption of oats in celiac disease patients is the scarcity of long-term studies [8, 18]. More 
information would be needed, in particular regarding histological and serological healing and 
quality of life.  
In Finland, oats has traditionally been a major ingredient in the daily diet, and in purified form it 
was accepted more than 15 years ago and widely used among celiac disease patients [19]. This 
provided an excellent opportunity to compare long-term treatment outcomes between large and 
well-defined cohorts of patients on a GFD with or without oats. Additionally, we investigated 
factors associated with the introduction of oats as a part of the GFD at the time of the celiac disease 
diagnosis. 
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2. Materials and methods 
2.1. Patients and Study Design 
Previously diagnosed biopsy-proven celiac disease patients who had been on a GFD for variable 
periods of time were recruited by a nationwide search via newspaper advertisements and with the 
help of national and local celiac disease societies. The original diagnosis could have been made at 
any age, but in the present study only patients currently over 16 years of age were included. 
Exclusion criteria were unconfirmed diagnosis and markedly lacking medical information either 
before or at the time of the diagnosis. After entering the study, all voluntary participants were 
interviewed with structured questions by an experienced physician or study nurse. The interviewers 
systematically established a variety of celiac disease-related clinical and demographic data as 
defined below in detail. Further, the participants filled structured gastrointestinal symptom and 
quality of life questionnaires, and laboratory samples were drawn for further serological analyses. 
Besides personal interviews, the medical records of each patient were scanned in order to confirm 
the celiac disease diagnosis and clinical data, and to further explore all relevant histological and 
serological findings and laboratory values. After data collection, the participants were divided into 
two groups based on the consumption or non-consumption of oats in their GFD, and all study 
variables were compared between these groups. 
The Ethical Committee of Pirkanmaa Hospital District approved the study design, patient 
recruitment, and data collection. Written informed consent was obtained from all enrolled 
participants. 
2.2. Clinical Information 
Demographic data, celiac disease in the family, time, and site (primary care, secondary care or 
tertiary care, private sector) of the diagnosis, clinical presentation (e.g., gastrointestinal symptoms, 
extraintestinal symptoms, and detected by screening), previous and current smoking, and the 
presence of celiac disease-associated (e.g., dermatitis herpetiformis, type 1 diabetes, and 
autoimmune thyroidal disease) or other chronic diseases and malignancies were established. In 
addition, the prevalence of osteoporosis, osteopenia, and any fractures was explored. The durations 
of symptoms before diagnosis (<1 year, 1–5 years, >5 years) and their severity (mild, moderate, 
severe) both at diagnosis and at present were recorded. The year of the diagnosis was further sub-
classified as before 1990, between 1990 and 1999, and after 2000. The interviewers also inquired 
whether participants had regular follow-up by health care. 
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2.3. Serology and Histology 
Current serum IgA-class endomysial (EmA) and transglutaminase 2 (TG2ab) antibody values were 
measured in all participants upon study entry. EmA was assessed by indirect immunofluorescence 
using a human umbilical cord as substrate. Titers of 1:≥5 were considered positive and further 
diluted up to 1:4000 until negative. TG2ab were assessed by commercial enzyme-linked 
immunosorbent assay (QUANTA Lite h-tTG IgA, INOVA Diagnostics, San Diego, CA, USA), and 
values >40 U/L were considered positive. The corresponding IgG-class EmA and TG2ab antibodies 
were measured in patients with selective IgA deficiency. Since normalization of the antibodies on a 
GFD may take some time [8, 19, 20], subjects dieting for less than two years were excluded from 
the serological follow-up analyses.  
Results of diagnostic and follow-up biopsies after one year on GFD were collected from the 
hospital pathology reports. In our clinical routine, several small-bowel mucosal biopsies are taken 
from each patient both upon celiac disease suspicion and during the follow-up endoscopy. The 
histological samples are then forwarded to the pathology department, where well-orientated 
specimens are carefully evaluated according to our standard operating procedures [21]. Severity of 
mucosal damage is further categorized as partial (PVA), subtotal (SVA), or total (TVA) villous 
atrophy, these corresponding roughly to Marsh–Oberhüber grades IIIa, IIIb, and IIIc. 
2.4. Questionnaires 
Self-perceived gastrointestinal symptoms were investigated with a validated Gastrointestinal 
Symptom Rating Scale (GSRS) questionnaire. The survey consists of 15 separate queries, which 
can be divided into five sub-domains: indigestion, diarrhea, constipation, abdominal pain, and 
reflux. Each sub-score is calculated as the average of three relevant items and the total score as the 
average of all 15 items. Answers are scored using a seven-grade Likert scale (possible points from 1 
to 7) with higher scores denoting more severe gastrointestinal symptoms [22].  
The Short-Form 36 Health Survey (SF-36) was used to assess quality of life and general health [23, 
24]. It comprises 36 items representing eight different sub-sections: physical functioning, physical 
role limitations, emotional role limitations, vitality, mental health, social functioning, bodily pain, 
and general health. Each item is scored from 0 to 100, and the items in the same section are 
averaged together to form the eight separate sub-dimensions. Higher scores indicate better health 
and social functioning.  
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The Psychological General Well-Being (PGWB) questionnaire is another widely used measure of 
quality of life and general well-being [25]. PGWB consists of 22 questions representing six 
different sub-domains as follows: anxiety, depression, well-being, self-control, general health, and 
vitality. The items use a six-grade scale (points from 1 to 6) and the scores are added together in 
each different sub-domain and as a total score that can range from 22 to 132 points. Higher scores 
indicate better health-related quality of life and well-being [26]. 
2.5. Gluten-Free Diet 
Duration and strictness of the GFD were asked from all participants. Self-reported dietary 
adherence was further classified as strict GFD (no lapses), occasional lapses (lapses less than once a 
month), and no GFD (more common lapses). In addition, the source of dietary advice at the time of 
diagnosis was established and categorized as no advice, dietitian, or other (e.g., physician or nurse). 
Finally, regular consumption of oats as part of the GFD was asked about and classified as either use 
or no use. The GFD label may be used for uncontaminated oats products that contain gluten less 
than 20 parts per million. 
2.6. Statistical Analysis 
Categorical variables are presented as percentages and continuous variables as medians with ranges 
or with quartiles as appropriate. Categorical variables were compared using cross-tabulation with a 
chi-square test. To compare medians between the study groups, the non-parametric Mann–Whitney 
U test was used. All statistical analyses were made using SPSS version 23. P-values < 0.05 were 
considered statistically significant. Age and sex were considered as possible confounding factors in 
each analysis. 
 
3. Results 
3.1. Baseline Data and Factors Predicting Oat Consumption 
Altogether 869 individuals (median age 53 years, females 75.5%) fulfilled the study criteria and 
were enrolled. Of these, 715 (82%) consumed oats as part of their GFD. At the time of celiac 
disease diagnosis 4.4% of the participants were under 16 years of age. Oat-consumers were a few 
years older at diagnosis, while there was no difference in gender distribution (Table 1). Factors 
predicting oat-consumption in the GFD were celiac disease diagnosis after the year 2000, detection 
of the disease by screening, mild clinical presentation at diagnosis, and dietary advice given by a 
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dietitian. The consumption of oats was not dependent on family history of celiac disease, site of 
diagnosis, duration of symptoms before diagnosis, or severity of small-bowel mucosal damage 
(Table 1). 
3.2. Follow-Up Results 
There were no significant differences in current ages between the two study groups, but those 
consuming oats had on average been a shorter time on a GFD before enrolment (Table 2). However, 
patients in both groups had been on a GFD approximately a median of 10 years (Table 2). They 
reported excellent and comparable dietary adherence, and there were also no significant differences 
between the groups in current self-reported symptoms, results of follow-up biopsy or prevalence of 
celiac disease autoantibody positivity (Table 2). In addition, the median TG2ab values were at the 
same level (oats 12.0 U/L vs. no oats 10.0 U/L, p = 0.077).  
The study groups did not differ in the prevalence of osteoporosis, fractures, or malignancies, but 
subjects on the oat-containing GFD were less often current smokers (Table 2). Further, they were 
more often completely free of other chronic diseases (16.9% vs. 10.4%, p-value = 0.044). In more 
detailed analysis, however, no significant differences between the groups were found in the 
prevalence of any specific celiac disease-associated condition (e.g., type 1 diabetes or autoimmune 
thyroidal disease) or other chronic disease when categorized into major disease groups (metabolic, 
endocrinological, hematologic, immunologic, ophthalmologic, otolaryngological, 
gastroenterological, psychiatric, respiratory, locomotor, neurological, gynecological, urologic, and 
cardiovascular disorders) (data not shown). Furthermore, there was no significant difference 
between oat consumers and non-consumers in attendance for regular follow-up by health care 
(Table 2).  
In line with the current self-estimated overall symptoms, the groups showed no difference in GSRS 
total or any sub-dimension scores (Table 3). There was no difference in health-related quality of life 
when measured by PGWB total and sub-scores, but in SF-36 oat-consumers yielded better scores on 
physical role limitations and general health (Table 3). 
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Table 1. Clinical and histological characteristics and presence of dietary advice at diagnosis in 
869 celiac disease patients currently on a gluten-free diet with or without oats 
  
Oats 
n=715 
  
No oats 
n=154 
  
 % % P value 
Age at diagnosis, median (range), years 43 (1-81) 41 (1-79) 0.048 
Females 75.9 73.4 0.502 
Celiac disease in the family 66.9 66.0 0.824 
Site of diagnosis   0.789 
Primary care 14.4 12.3  
Secondary care or tertiary care 72.7 74.0  
Private sector 12.9 13.6  
Year of diagnosis    <0.001 
<1990 16.4 32.5  
1990-1999 33.3 31.2  
2000- 50.3 36.4  
Clinical presentation at diagnosis   0.004 
Gastrointestinal symptoms
1
 56.6 65.6  
Extraintestinal symptoms
2
 28.1 29.2  
Screen-detected in at-risk groups
3
 15.2 5.2  
Severity of symptoms before diagnosis
4 
  0.006 
No or mild 37.2 23.7  
Moderate 12.6 9.6  
Severe 50.2 66.7  
Duration of symptoms before diagnosis   0.186 
<1 year 22.2 24.3  
1-5 years 35.8 27.8  
>5 years 42.0 47.9  
Diagnostic histology   0.726 
Total villous atrophy 26.4 24.0  
Subtotal villous atrophy 37.6 41.3  
Partial villous atrophy 36.0 34.7  
Dietary advice at diagnosis   0.006 
No advice 19.7 27.2  
Dietitian 69.3 55.8  
Physician/nurse/other 11.0 17.0  
1 
E.g. abdominal pain, constipation, diarrhea, malabsorption; 
2
 E.g. arthritis, dental enamel 
defects, infertility, neurologic symptoms, osteoporosis; 
3
 E.g. relatives of the patients and 
subjects with type 1 diabetes mellitus or autoimmune thyroidal disease 
Data were available in >90% of the subjects in each category except in 
4
74% and 
5
63% 
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Table 2. Age at the current study and a variety of follow-up data in 869 celiac disease patients 
currently on a gluten-free diet (GFD) with or without purified oats 
  
Oats 
n=715 
  
No oats 
n=154 
  
 % % P value 
Age at present, median (range), years 53 (17-89) 55 (21-85) 0.716 
Time on GFD, median (range), years 9 (1-47) 13 (1-53) <0.001 
Current self-reported dietary adherence   0.746 
Strict GFD 96.5 97.4  
Occasional lapses 3.2            2.6  
No GFD 0.3 0.0  
Current self-reported symptoms   0.931 
No 75.5 75.5  
Mild or moderate 22.9 22.5  
Serious 1.6 2.0  
Follow-up histology on a GFD
1
   0.773 
Healed mucosa 63.1 60.0  
Inflammation/partial villous atrophy 33.5 35.3  
Subtotal/total villous atrophy 3.4 4.7  
Follow-up serology on a GFD2    
Positive EmA 8.8 6.0 0.273 
Positive TG2ab           12.2 10.1 0.471 
TG2ab value, median, U/l 12.0 10.0 0.077 
Any malignancy 4.8 3.3 0.420 
Osteoporosis or osteopenia 9.2 11.0 0.489 
Any fracture 26.9 27.9 0.791 
Current smoking 8.2 14.9 0.009 
Regular follow-up by the health care 29.0 28.7 0.926 
Data were available in >90% of the subjects in each variable except in follow-up histology 54% 
1
Follow-up biopsy was taken after a median of one year (range 1-25 years) in both groups 
2
Patients with a GFD less than two years were excluded from the analysis 
EmA, endomysial antibodies; TG2ab, transglutaminase 2 antibodies 
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Table 3. Gastrointestinal Symptom Rating Scale (GSRS), Short-form (36) Health Survey (SF-36) 
and Psychological General Well-being (PGWB) questionnaire scores in 590 celiac disease patients 
currently on a gluten-free diet with or without oats 
  
Oats 
n=484 
  
No oats 
n=106 
  
 Median Quartiles Median Quartiles P value 
GSRS scores
1
      
Total 1.9 1.5-2.5 2.0 1.5-2.7 0.460 
Indigestion 2.3 1.8-3.3 2.5 1.7-3.3 0.864 
Diarrhea 1.3 1.9-2.3 1.7 1.0-2.3 0.164 
Constipation 1.7 1.0-2.7 2.0 1.0-2.7 0.318 
Abdominal pain 2.0 1.3-2.3 2.0 1.3-2.7 0.506 
Reflux 1.5 1.0-2.0 1.5 1.0-2.5 0.329 
SF-36 scores
2
      
Physical Functioning 95 80-100 90 69-100 0.081 
Role limitations, physical 100 50-100 75 25-100 0.020 
Role limitations, emotional 100 67-100 100 67-100 0.802 
Vitality 70 55-85 70 55-85 0.808 
Mental health 80 72-88 84 68-92 0.701 
Social functioning 88 75-100 88 75-100 0.470 
Bodily pain 78 58-90 68 49-90 0.532 
General health 65 50-80 60 40-75 0.048 
PGWB sub-scores
3
      
Total 106 94-115 104 95-116 0.526 
Anxiety 25 21-27 25 22-27 0.658 
Depression 17 15-18 16 15-18 0.215 
Well-being 18 15-20 17 14-20 0.628 
Self-control 16 14-17 16 14-17 0.952 
General health 13 11-15 13 10-15 0.128 
Vitality 18 16-20 18 16-21 0.515 
Higher scores denote either 
1
more severe symptoms, 
2
better health and social functioning or 
3
better 
health-related quality of life. 
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4. Discussion 
We demonstrated that celiac disease patients consuming oats as part of a longstanding GFD did not 
differ in symptoms and celiac serology, and had similar or even somewhat better quality of life 
from those not consuming oats. Further, there was no difference between the groups in small-bowel 
mucosal damage in control biopsy after one year on a GFD. These findings are in line with most 
previous short-term studies showing no harm from oat consumption in celiac disease patients [7, 9, 
10], and further strongly support the long-term safety of oats.  
One of our aims was to explore factors associated with the introduction of oats as part of the GFD, 
an issue regarding which there are no previous scientific data. We found oats to be significantly 
more widely consumed among patients diagnosed after the year 2000 than by those diagnosed 
earlier. This might be partly a result of physicians’ increased acceptance of oats in the celiac diet. 
Patients diagnosed by screening and with less severe symptoms were also more likely to consume 
oats, possibly since they and their physicians are less hesitant to try oats in cases of mild clinical 
presentation. This is very likely further attributed to the increasing consumption of oats over time, 
as the screening of celiac disease has also increased during the 2000s [27]. Interestingly, patients 
who visited dietitians consumed oats more often than those receiving dietary advice from other 
health care professionals. Dietitians generally have a slightly different perspective on chronic 
diseases than clinicians [28], and in celiac disease patients they may focus more on the nutritional 
benefits of oats and recommend it if not specifically forbidden by the responsible physician.  
Of note regarding issues not associated with the introduction of oats was the level of health care at 
which the diagnosis was made. This might not necessarily have been pertinent, as it has 
beenreported that the treatment of chronic diseases differs significantly between general 
practitioners and specialists [29]. The more uniform results in Finland might be due to the widely 
used nationwide treatment guidelines for celiac disease [30] and the increasing transfer of the 
diagnostics from tertiary centers to primary care [27]. We believe that the constantly rising number 
of celiac patients makes such a decentralization necessary, and there should not be major 
differences in implementation of the GFD between different levels of health care.  
One main finding among long-term outcomes was the absence of any difference between oats and 
no-oats groups in either self-reported overall symptoms or those measured by validated 
questionnaire. This is in line with most previous short-term studies [7, 9, 10, 31] and our recent 
smaller follow-up study [8], in which oats did not increase symptoms on a GFD. However, in our 
earlier randomized trial oat-consumers reported more diarrhea than those without oats [11], and in a 
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12-week challenge study from Norway some celiac patients experienced abdominal discomfort and 
bloating when starting oats [12]. However, since any rapid change in the amount of dietary fiber can 
cause gastrointestinal symptoms even in non-celiacs [32], the reaction to fiber-rich oats might be 
only a matter of nonspecific adaptation rather than true immunological activation. In fact, also in 
the two aforementioned studies [11, 12], most patients with initial symptoms later tolerated oats as a 
part of their GFD. Oats may thus cause symptoms in a small group of celiac patients, but they are 
usually mild and avoidable by a gradual increase in daily consumption.  
Another important result here was the equal self-perceived quality of life in the oats and no-oats 
groups as measured by validated PGWB and SF-36 questionnaires. In fact, oat-consumers had even 
somewhat fewer physical role limitations and better general health when measured by the SF-36. 
Similarly, oat consumption was not associated with decreased quality of life in the above-mentioned 
randomized trial from our group [11], and in another study celiac patients reported oat consumption 
as making the GFD easier to maintain by diversifying the diet nutritionally, lowering costs and 
improving taste [33]. Interestingly, in the current study, we also found oat-consumers to smoke less. 
This indicates in general a healthier lifestyle, which apparently helps maintain good health and 
quality of life.  
The consumption of oats also did not predispose to a higher risk of celiac antibody positivity or 
histological damage on a GFD. This is especially important given that the long-term complications 
of celiac disease are considered to be a consequence of an ongoing intestinal lesion, whose severity 
the antibody levels also reflect [34]. The excellent morphological mucosal recovery with oats is in 
line with the findings in our randomized study [11] and more recent studies [8, 35, 36]. In the first 
[11] and last [36] of these studies, oat consumers evinced a slightly higher density of duodenal 
intraepithelial lymphocytes (IELs). The increase was, however, seen mostly in so-called γδ+ IELs, 
of which eventual significance is unclear and not necessary pathologic. Moreover, the increased 
levels of IELs had no effect whatsoever on the other measured outcomes and was not seen in the 
other two studies [8, 35]. The fact that the histological damage was not fully healed at the one year 
control biopsy in up to 40% of the patients in both oats and no oats groups here does not reflect 
poor dietary adherence, but instead is in line with previous studies showing that, despite a strict 
GFD, the villous recovery often takes a considerably longer time to recover [36]. Our results are 
supported by studies from other groups also showing no effect of oats in recovery of the villous 
architecture [18, 37–40]. Nevertheless, one patient in the above-mentioned Norwegian study [12] 
developed villous atrophy while using purified oats, and in experimental models of celiac disease, 
certain oat cultivars have triggered immunological responses [27]. There are also reports of altered 
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epithelial function and avenin-specific T-cell stimulation in a part of patients on a GFD with oats 
[39, 41]. Although these issues need further clarification, true intolerance to oats would appear to be 
very rare in clinical practice. The safety of oats in the long term was further supported by the equal 
incidence of malignancies, osteoporosis, and fractures between our study groups. We would also 
emphasize that, although oats are widely consumed among Finnish patients (here 82%), treatment 
results are very good and refractory celiac disease is exceptionally rare [42].  
Our main strengths were the large study groups with and without oats, the long follow-up time on a 
GFD, and the use of validated questionnaires for symptoms and quality of life. We also succeeded 
in collecting a wide variety of clinically relevant follow-up data. One limitation, on the other hand, 
was that reasons behind the non-consumption of oats were not investigated, and it is possible that in 
some cases it was initially tried but later omitted due to clinical symptoms [33]. We also had no 
data as to the exact individual amounts or cultivars of oats consumed, but this reflects the real life 
setting in which the daily consumption varies substantially both between and within individuals. 
The mean intake of oats in Finland is approximately 18 g per capita per day [43], and in our 
previous study [8], the patients consumed 20 g oats per day. Thus, we can assume that the 
participants were consuming approximately the same amount of oats as the population in general. 
Another factor we could not control here was that, earlier, the patients might have consumed the so-
called naturally gluten-free products of which gluten content was not certified. We also had no data 
as to the exact individual amounts of oats consumed, but this reflects the real life setting in which 
the daily consumption varies substantially both between and within individuals. The fact that a part 
of the participants were members of the celiac society might have caused a selection bias. It is also 
good to remember that, in Finland, products with purified oats are widely available and strictly 
regulated [19], and caution is thus warranted before generalizing our results to countries with less 
experience with such groceries.  
To conclude, we provided strong evidence that the consumption of oats as part of the GFD is safe 
also in the long term in the great majority of celiac disease patients. Considering the various health 
benefits related to the regular consumption of oats, we encourage physicians to recommend it with a 
low threshold. It is important to ensure the purity and high quality of oat-containing GFD products 
[44], and, as always in celiac disease patients, careful monitoring for an adequate response to 
dietary treatment is mandatory. 
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